GET DAILY SIGNALSSummit Therapeutics (SMMT) Q3 2026 Earnings Preview: Focus Shifts to Clinical Updates and FDA Timeline
Key Takeaways
- Summit Therapeutics (SMMT) is expected to report results for the third quarter ended September 30, 2026, around November 11, 2026, based on its prior reporting schedule.
- Wall Street consensus points to a net loss of roughly $0.28 per share, with revenue remaining essentially zero as the company is still pre-commercial.
- Investors will likely pay more attention to clinical and regulatory updates than to the financials, given the upcoming November 14, 2026 FDA decision on ivonescimab.
- Cash, cash equivalents, and short-term investments stood at about $690.7 million at the end of the second quarter, supporting ongoing late-stage trials.
- Key catalysts ahead include final HARMONi-3 squamous-cell progression-free survival (PFS) data expected in the second half of 2026.
- Operating expenses have climbed sharply in recent quarters on expanded research and development (R&D) activity and higher stock-based compensation.
Earnings Context and Why It Matters
Summit Therapeutics is a clinical-stage biopharmaceutical company with no marketed product in the United States, so its quarterly results are shaped more by spending patterns than by revenue. In my view, the Q3 2026 report will matter primarily for insights into the cash position, expense trajectory, and any management commentary around ivonescimab, the lead drug candidate. This bispecific antibody targets both PD-1 and VEGF pathways that play roles in cancer growth and immune evasion. With an FDA approval decision set for just days after the expected earnings release, the report lands at a critical juncture. I’m watching closely for any updates on trial timelines, launch preparations, or funding plans for continued development.
Earnings Expectations
Analysts expect Summit Therapeutics (SMMT) to post a net loss of approximately $0.28 per share for the third quarter of 2026, according to consensus estimates. Revenue forecasts stay negligible given the pre-commercial stage. Traditional revenue and earnings comparisons offer limited value here, so attention turns instead to R&D spending, general and administrative costs, and cash burn rates. For context, the company reported a second-quarter 2026 loss amid rising operating expenses tied to three Phase III programs. R&D costs have increased substantially year over year due to clinical trial activity and infrastructure work ahead of a potential launch. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors will likely monitor any reaffirmation of the capital position and updates on at-the-market financing facilities.
Market Reaction and Investor Sentiment
Sentiment heading into the Q3 2026 report remains closely linked to clinical developments rather than the numbers themselves. Earlier in 2026, shares declined after an independent data monitoring committee recommended that the HARMONi-3 trial continue as planned without pursuing an early regulatory path for the squamous-cell cohort. That move removed a potential near-term catalyst and highlighted how sensitive the stock is to trial and regulatory news. From what I see, investors will weigh the company’s solid cash balance and late-stage pipeline against ongoing losses and clinical risks. Commentary on the HARMONi-3 data timeline or launch readiness ahead of the November 14, 2026 FDA decision could influence the shares more than the reported loss.
Forward Outlook and Key Factors to Monitor
The most important near-term event is the FDA’s Prescription Drug User Fee Act goal date of November 14, 2026, for ivonescimab in EGFR-mutated non-small cell lung cancer. A positive decision would signal a shift toward commercialization and alter the financial profile. Beyond that, final PFS data from the squamous-cell cohort of HARMONi-3 is expected in the second half of 2026. This trial compares ivonescimab with Merck’s Keytruda in first-line metastatic non-small cell lung cancer, making its outcome a significant value driver. Longer-term catalysts include an interim overall survival analysis in the first half of 2027, enrollment updates in the HARMONi-7 and HARMONi-GI3 studies, and early data from the GSK collaboration announced earlier in 2026. On the financial front, watch cash burn, any additional equity raises, and management’s comments on commercial infrastructure spending. As with other development-stage biotechs, trial results and regulatory decisions remain the primary risks.
Using AI Tools for Deeper Analysis
In my own workflow, I frequently rely on Tickeron’s AI Screener to quickly scan for comparable names and technical setups around earnings events. The tool lets me filter by fundamentals, volatility, and AI-driven signals, which helps surface context without manual effort. It has become a practical addition when preparing for reports like this one from Summit Therapeutics (SMMT).
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SMMT in upward trend: price may jump up because it broke its lower Bollinger Band on September 25, 2026
SMMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 35 cases where SMMT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 69 cases where SMMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +9.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where SMMT advanced for three days, in 244 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 124 of 148 cases where SMMT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SMMT as a result. In 84 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for SMMT turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 39 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
SMMT moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SMMT crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. SMMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.361) is normal, around the industry mean (3.035). P/E Ratio (-13.063) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel medicines
Industry Biotechnology
Advertisement